Maid PJ, et al. - Researchers evaluated the antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit and correlate it with efficacy outcomes. In this subset analysis of a noninterventional, multinational, cross-sectional study they evaluated adult patients with RA treated continuously for 6 to 24 months with etanercept, adalimumab, or infliximab for ADAs and trough drug concentrations of 2 days or less prior to the next scheduled dose. Findings suggested that ADAs was seen to be positive in RA patients from Argentina treated with adalimumab or infliximab, but not etanercept. A tendency toward better clinical outcomes was seen in the antidrug antibody–negative patients vs ADA-positive patients.